Ponderile din venituri sunt estimări pentru nine months ended September 30, 2026, nu cifre dintr-un raport depus.
SPINRAZA
An injected medicine for spinal muscular atrophy, a disease that causes muscle weakness.
TYSABRI
An infusion medicine for relapsing multiple sclerosis.
LEQEMBI
An antibody medicine for early Alzheimer’s disease, developed and sold with Eisai.
SKYCLARYS
A medicine for Friedreich ataxia, an inherited disease that affects movement and coordination.
SYFOVRE
An eye injection for geographic atrophy, a disease that can cause central vision loss.
EMPAVELI
A medicine for a rare blood disorder and certain rare kidney diseases.
Situațiile financiare complete →
Biogen discovers, develops and sells medicines for neurological, immune-system and rare diseases. Its products include treatments for multiple sclerosis, spinal muscular atrophy, Alzheimer’s disease and certain eye, kidney and blood disorders. It develops and commercializes some medicines with other drug companies, sharing costs, sales or profits under those agreements.
Construit din raportările proprii ale Biogen Inc. la Comisia pentru Valori Mobiliare și Burse a SUA (SEC). Cifrele sunt cele raportate, iar istoricul pe acțiune este recalculat la baza de acțiuni de azi. Aceasta descrie o afacere — nu este consultanță de investiții și nu este o recomandare de cumpărare sau vânzare.
253,51 USD+1,2 %închidere 13 nov.
Cifre până la 30 septembrie 2026, din 10-Q depus pe 28 octombrie 2026
Biogen sells prescription medicines for multiple sclerosis and rare diseases, including SPINRAZA for spinal muscular atrophy, through health-care providers.
Just reported
From Biogen's results release of 28 octombrie 2026; its quarterly report has since been filed.
Actual
2,8B USD
+11 % y/y
+2,5 % q/q
Guided
—
No guide given
Actual
-0,14 USD
Guided
—
No guide given
Full year 2026
Set against the company's own guidance and the same quarter a year earlier, not analysts' estimates, which we do not hold. Adjusted figures are the company's own non-GAAP measures, as stated in the release.
The themes Biogen is part of, the highest-graded companies in its industry, and the companies in its sector whose grade rose recently.
Graded A or B and worth $2B or more: A first, then the largest.
Rose to A or B on a filing in the last 90 days, worth $2B or more: largest first.
Grade A
Banda de sub preț arată nota la fiecare dată, calculată doar din documentele publice până atunci.
Se afișează 2 din 40 trimestre din istoricul notelor companiei Biogen Inc.. Celelalte 38 merg înapoi până în octombrie 2016.
